Literature DB >> 29042836

Evaluation of the Effects of Extracorporeal Membrane Oxygenation on Antiepileptic Drug Serum Concentrations in Pediatric Patients.

Nicholas O Dillman1, Mindl M Messinger1, Kimberly N Dinh1, Jennifer L Placencia1, Brady S Moffett1, Milenka Cuevas Guaman1, Jennifer C Erklauer1, Jeffrey R Kaiser1, Angus A Wilfong1.   

Abstract

OBJECTIVES: Patients supported on extracorporeal membrane oxygenation (ECMO) have an increased incidence of seizures. Phenobarbital (PB) and fosphenytoin (fos-PHT) are common antiepileptic drugs (AEDs) used to manage seizures in the pediatric population; however, it is unknown what effect ECMO has on the serum concentrations of AEDs. The purpose of this study is to evaluate the effect of ECMO on AED serum concentrations.
METHODS: A retrospective, matched-cohort study was performed in patients younger than 18 years who received ECMO and were treated with intravenous (IV) PB or fos-PHT at Texas Children's Hospital between 2004 and 2014. Patients receiving IV AED therapy and ECMO were matched, based on age, sex, and weight, with patients receiving IV AED therapy without ECMO. The 24-hour cumulative AED dose, serum concentrations, number of doses per serum concentration drawn ratio, volume of distribution, therapeutic serum concentrations, and time to therapeutic serum concentration were compared between both groups. The fos-PHT and PB groups were analyzed in all patients and in neonates only.
RESULTS: Fourteen patients met inclusion criteria. The fos-PHT neonatal (20.1 vs 11.3 mg/kg/day, p = 0.044), PB composite (33.9 vs 21.6 mg/kg/day, p = 0.012), and PB neonatal (40.3 vs 20 mg/kg/day, p = 0.04) had larger 24-hour cumulative doses compared with non-ECMO patients. Lower serum concentrations were observed in the PB composite ECMO group (19.1 vs 35.4 mg/L, p < 0.001) and the PB neonatal ECMO group (20.5 vs 27.8 mg/L, p = 0.01) compared with non-ECMO patients.
CONCLUSION: Pediatric patients receiving PB on ECMO and neonatal patients receiving fos-PHT on ECMO required larger doses, and in pediatric patients achieved lower serum concentrations, suggesting the necessity for alternative dosing strategies in these populations.

Entities:  

Keywords:  antiepileptic drugs; extracorporeal membrane oxygenation; fosphenytoin; neonates; pediatrics; phenobarbital

Year:  2017        PMID: 29042836      PMCID: PMC5640302          DOI: 10.5863/1551-6776-22.5.352

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  9 in total

1.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment.

Authors:  Nilesh M Mehta; David R Halwick; Brenda L Dodson; John E Thompson; John H Arnold
Journal:  Intensive Care Med       Date:  2007-04-03       Impact factor: 17.440

2.  Clinical pharmacokinetics of phenobarbital in neonates.

Authors:  D J Touw; O Graafland; A Cranendonk; R J Vermeulen; M M van Weissenbruch
Journal:  Eur J Pharm Sci       Date:  2000-12       Impact factor: 4.384

3.  Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation.

Authors:  E S Elliott; M L Buck
Journal:  Ann Pharmacother       Date:  1999-04       Impact factor: 3.154

4.  Neurologic complications in neonates supported with extracorporeal membrane oxygenation. An analysis of ELSO registry data.

Authors:  Angelo Polito; Cindy S Barrett; David Wypij; Peter T Rycus; Roberta Netto; Paola E Cogo; Ravi R Thiagarajan
Journal:  Intensive Care Med       Date:  2013-06-08       Impact factor: 17.440

5.  Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach.

Authors:  Amélie Marsot; Véronique Brevaut-Malaty; Renaud Vialet; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Fundam Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.748

6.  Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs.

Authors:  O Dagan; J Klein; C Gruenwald; D Bohn; G Barker; G Koren
Journal:  Ther Drug Monit       Date:  1993-08       Impact factor: 3.681

7.  The association of carotid artery cannulation and neurologic injury in pediatric patients supported with venoarterial extracorporeal membrane oxygenation*.

Authors:  Sarah A Teele; Joshua W Salvin; Cindy S Barrett; Peter T Rycus; Francis Fynn-Thompson; Peter C Laussen; Ravi R Thiagarajan
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

Review 8.  Neurologic complications and neurodevelopmental outcome with extracorporeal life support.

Authors:  Amit Mehta; Laura M Ibsen
Journal:  World J Crit Care Med       Date:  2013-11-04

9.  Phenobarbital use in an infant requiring extracorporeal membrane life support.

Authors:  Brian Schloss; Don Hayes; Joseph D Tobias
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-01
  9 in total
  4 in total

Review 1.  What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?

Authors:  Martin Šíma; Danica Michaličková; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

2.  Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.

Authors:  Céline Thibault; Shavonne L Massey; Nicholas S Abend; Maryam Y Naim; Alexandra Zoraian; Athena F Zuppa
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

3.  Population Pharmacokinetics of IV Phenobarbital in Neonates After Congenital Heart Surgery.

Authors:  Céline Thibault; Shavonne L Massey; Maryam Y Naim; Nicholas S Abend; Athena F Zuppa
Journal:  Pediatr Crit Care Med       Date:  2020-08       Impact factor: 3.971

4.  Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review.

Authors:  Natalia Sutiman; Janine Cynthia Koh; Kevin Watt; Christoph Hornik; Beverly Murphy; Yoke Hwee Chan; Jan Hau Lee
Journal:  Front Pediatr       Date:  2020-06-26       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.